Effects of a synthetic PEG-ylated Tie-2 agonist peptide on endotoxemic lung injury and mortality.

David S, Ghosh CC, Kümpers P, Shushakova N, Van Slyke P, Khankin EV, Karumanchi SA, Dumont D, Parikh SM. Am J Physiol Lung Cell Mol Physiol. 2011 Jun;300(6):L851-62.

https://www.ncbi.nlm.nih.gov/pubmed/21421750

About

Vasomune Therapeutics is a private biotechnology company developing Pegevongitide (AV-001), a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor. Activation of the Tie2 receptor by Pegevongitide plays a critical role in improving vascular stability, barrier integrity and endothelial quiescence.

Effects of a synthetic PEG-ylated Tie-2 agonist peptide on endotoxemic lung injury and mortality.

About

Vasomune Therapeutics 2025 © All Rights Reserved.